-+ 0.00%
-+ 0.00%
-+ 0.00%

Pharming Projects 2026 Revenue Of $405M To $425M, Driven By Joenja And RUCONEST Growth, With Operating Expenses Between $330M And $335M

Benzinga·02/03/2026 06:37:24
Listen to the news
  • Highlights advancing clinical-stage pipeline, including two major value-creating programs for primary immunodeficiencies (PIDs) with immune dysregulation and mtDNA-driven mitochondrial disease
  • Introduces napazimone (KL1333) as the compound name for the mtDNA-driven mitochondrial disease program
  • 2026 total revenue guidance of US$405 – US$425 million (8% to 13% growth)
  • 2026 total operating expense guidance of US$330 – US$335 million